Annovis Bio Buntanetap Phase II/III shows statistically significant efficacy in APOE4 Alzheimer's patients

Annovis Bio, Inc.

In early AD patients (MMSE 21-24), Buntanetap showed -3.3 point ADAS-Cog11 improvement vs baseline and -2.3 vs placebo.
APOE4 carriers on 15mg dose achieved -3.15 point improvement in ADAS-Cog11 scores.
Buntanetap had no ARIA or serious drug-related TEAEs; safety comparable in carriers and non-carriers.
Study included 159 APOE4 carriers (33 homozygotes) and 159 non-carriers.
Company plans 18-month Phase III trial in biomarker-positive early AD patients under FDA guidance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.